Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GMNN | O75496 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Ion SCHEMBL7626187 | 0.97 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL2510689 | 0.97 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL27537025 | 0.93 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL27689103 | 0.92 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL27445764 | 0.92 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL609998 | 0.86 | MEN1 (0.61) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL3446901 | 0.86 | MEN1 (0.61) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL30274683 | 0.86 | MEN1 (0.61) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL506775 | 0.86 | MEN1 (0.61) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL3446899 | 0.86 | MEN1 (0.61) | LMNASMN1; SMN2CYP1A2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245537-A1 | L-carnitine calcium fumarate, preparation method and application for the same | Liaoning Konepnutra Co., Ltd | 2011-10-06 | — | — | US | claimed |
| EP-2125700-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | Shenyang Koncepnutra Corporation, Limited (CN) | 2009-12-02 | — | — | EP | claimed |
| US-20090281183-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2009-11-12 | — | — | US | claimed |
| WO-2008080287-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2008-07-10 | — | — | WO | claimed |
| US-10583111-B2 | Method for preventing or treating diseases associated with the inhibition of EGFR | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2020-03-10 | — | — | US | disclosed |
| US-20190282536-A1 | METHOD FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH THE INHIBITION OF EGFR | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-09-19 | — | — | US | disclosed |
| JP-5290975-B2 | — | — | 2013-09-18 | — | — | JP | disclosed |
| US-20110245537-A1 | L-carnitine calcium fumarate, preparation method and application for the same | Liaoning Konepnutra Co., Ltd | 2011-10-06 | — | — | US | disclosed |
| US-20110245537-A1 | L-carnitine calcium fumarate, preparation method and application for the same | Liaoning Konepnutra Co., Ltd | 2011-10-06 | — | — | US | disclosed |
| US-20110245537-A1 | L-carnitine calcium fumarate, preparation method and application for the same | Liaoning Konepnutra Co., Ltd | 2011-10-06 | — | — | US | disclosed |
| CN-101209975-B | Levulorotation carnitine calcium fumarate and its preparing method and use | SHENYANG KONCEPNUTRA CO LTD | 2010-12-01 | — | — | CN | disclosed |
| EP-2125700-A4 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORP LTD (CN) | 2009-12-23 | — | — | EP | disclosed |
| US-20090281183-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2009-11-12 | — | — | US | disclosed |
| US-7572832-B2 | Non-hygroscopic L-carnitine salts | BIOLINK LIFE SCIENCES, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080234371-A1 | Non-hygroscopic L-carnitine salts | BIOLINK LIFE SCIENCES, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008115915-A2 | NON-HYGROSCOPIC L-CARNITINE SALTS | BIOLINK LIFE SCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008080287-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080287-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080287-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2008-07-10 | — | — | WO | disclosed |
| CN-101209975-A | Levulorotation carnitine calcium fumarate and its preparing method and use | SHENYANG DONGYU FINE CHEMICAL (CN) | 2008-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282536-A1 | METHOD FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH THE INHIBITION OF EGFR | EGFR, ERBB2, KIT | LMNA 3229/4885SMN1; SMN2 4537/4885CYP1A2 3010/4885 |
| US-20090281183-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SLC25A20, FH, CA2 | LMNA 679/4885SMN1; SMN2 685/4885CYP1A2 3035/4885 |
| US-20110245537-A1 | L-carnitine calcium fumarate, preparation method and application for the same | SLC25A20, FH, CA2 | LMNA 681/4885SMN1; SMN2 691/4885CYP1A2 3057/4885 |
| US-20080234371-A1 | Non-hygroscopic L-carnitine salts | CRAT, SLC25A20, CPT1B | LMNA 420/4885SMN1; SMN2 998/4885CYP1A2 2226/4885 |
| US-10583111-B2 | Method for preventing or treating diseases associated with the inhibition of EGFR | EGFR, ERBB2, KIT | LMNA 3229/4885SMN1; SMN2 4537/4885CYP1A2 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.